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Abstract 
Oxygen heterocycles, in particular tetrahydropyrans and tetrahydrofurans, are common structural 
features of many biologically active polyketide natural products. Mupirocin is a clinically important 
antibiotic isolated from Pseudomonas fluorescens and is assembled on a tetrahydropyran ring which 
is essential for bioactivity. However, the biosynthesis of this moiety has remained elusive. Here we 
show an oxidative enzyme-catalysed cascade that generates the tetrahydropyran ring of mupirocin. A 
Rieske non-heme oxygenase (MupW) catalysed selective oxidation of the C8-C16 single bond in a 
complex acyclic precursor is combined with an epoxide hydrolase (MupZ) to catalyse the subsequent 
regioselective ring formation to give the hydroxylated tetrahydropyran. In the absence of MupZ, a 5-
membered tetrahydrofuran ring is isolated and model studies are consistent with cyclisation occurring 
via an epoxide intermediate. High resolution X-ray crystallographic studies, molecular modelling and 
mutagenesis experiments of MupZ provide insights into tetrahydropyran ring formation proceeding 
via an anti-Baldwin 6-endo-tet cyclisation.  
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Over many decades if not centuries, drug discovery has been inspired by natural products derived 
from microbes, plants and animals1. Natural products not only display valuable biological properties 
but often have complex and architecturally unique scaffolds. Elucidation of natural product 
biosynthetic pathways provides important insights into the assembly of potent bioactive molecules 
and often reveals unprecedented chemical and enzymatic platforms enabling the genetic 
manipulation of pathways to provide new compounds with improved properties towards stability 
and/or bioactivity2,3. 
Mupirocin, a mixture of polyketide-derived congeners consists of pseudomonic acids A (PA-A, 1, Fig. 
1a), B (2), and C (3) isolated from Pseudomonas fluorescens NCIMB 10586, is a clinically important 
antibiotic active against Gram-positive bacteria, including methicillin resistant Staphylococcus aureus 
(MRSA)4,5. It remains one of the most-effective treatments for MRSA, used mainly for topical skin 
infections and as a pre-operative nasal spray to combat hospital borne S. aureus infections. The 6,7-
dihydroxy-tetrahydropyran (THP) ring is essential for its antibiotic activity. Classical labelling studies 
and more recent genetic studies have established the biosynthetic origins of mupirocin6-10. It contains 
a polyketide moiety produced by a trans-AT modular polyketide synthase esterified by an unusual 9-
hydroxynonanoic acid moiety. The length of the fatty acid chain has a strong effect on its activity, 
which is due to inhibition of the isoleucyl tRNA synthetase of inter alia, E. coli and S. aureus11. Oxygen-
18 labelling has shown that the essential THP ring is formed by ether linkage from the 5-OH to the 16-
methyl group in a linear precursor (see e.g. Fig. 1c)6. A priori there are a number of chemically and 
biosynthetically precedented mechanisms for this cyclisation: electrophilic addition to an 8,16-alkene, 
conjugate addition onto an 8,16-dien-7-one, direct nucleophilic displacement on an activated 
derivative of the 16-methyl, or addition of the 5-OH to an 8,16-epoxide. The latter mechanism is given 
credence by the recent demonstration that PA-B, with an extra 8-hydroxyl group, is actually an 
intermediate in PA-A biosynthesis, being converted to PA-A in a complex sequence controlled by 7 
genes, involving 7 discrete intermediates, two of which are carrier protein-bound8-10. Oxygen 
heterocycles are widespread structural features of many biologically active polyketide natural 
products and gaining an understanding of how tetrahydropyrans (THPs) and tetrahydrofurans (THFs) 
are formed is of wide current interest world-wide12-14. 
We have previously shown that deletion of the dioxygenase MupW (and also of its redox partner 
MupT) in the mupirocin gene cluster abolished production of the PAs and led to accumulation of 
mupirocin W1 (6) which lacks the THP ring, but which now contains a new THF ring (Fig. 1b). It is 
proposed that the true biosynthetic intermediate is the linear compound 5 which undergoes 
spontaneous intra-molecular attack by the 7-OH onto the 10,11-epoxide9,15 (Fig. 1b). In support of this 
hypothesis, double inactivation of mupW and the oxidoreductase (OR) encoded by mmpE (identified 
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as responsible for 10,11-epoxidation) results in accumulation in the resulting mmpE∆OR/∆mupW 
mutant of P. fluorescens, albeit in very low titres of the much more stable, linear 
 
Figure 1. Summary of mupirocin biosynthesis in P. fluorescens NCIMB 10586. a, Key post-assembly steps in 
mupirocin biosynthesis. b, Structures of the proposed biosynthetic intermediate 5 which undergoes 
spontaneous cyclisation to mupirocin W1 (6) isolated from ΔmupW mutant. c, Structures of mupirocin W4 (7) 
and W5 (8) isolated from a mmpEΔOR/ΔmupW double mutant. d, Previously proposed mechanism of THP 
formation in mupirocin biosynthesis9. THP, tetrahydropyran. 
 
metabolites, mupirocin W4 (7) and W5 (8)9 (Fig. 1c). Thus, MupW and MupT appeared to be key 
enzymes in THP formation and we proposed that the oxygenase MupW together with its associated 
ferredoxin MupT catalyse oxidation of the C8-C16 single bond to an epoxide, which would then be 
opened by the 5-OH to form the THP ring and simultaneously install the 8-OH9 (Fig 1d). However, 
experimental proof for this is lacking and whether subsequent cyclisation to give the THP is a 
spontaneous process or if this reaction is also mediated by another enzymatic activity remained 
unclear.  
Intrigued by nature’s ability to selectively oxidise the non-activated C8-C16 single bond despite the 
presence of functional groups (double bonds and hydroxyl groups) elsewhere in the molecule (Fig. 1c, 
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boxed structure), herein we describe the reactions catalysed by MupW on mupirocin W4 (7) and W5 
(8) and show that formation of the THP ring requires the dual action of the dioxygenase MupW and 
an epoxide hydrolase MupZ, which had not previously been assigned a function. In the absence of 
MupZ, MupW catalyses formation of a 5-membered tetrahydrofuran and model studies are consistent 
with cyclisation occurring via an epoxide intermediate. High resolution X-ray crystallographic studies, 
molecular modelling and mutagenesis experiments of MupZ provide insights into tetrahydropyran ring 
formation proceeding via an anti-Baldwin 6-endo-tet cyclisation. 
 
Results 
MupW is a Rieske non-heme oxygenase 
Bioinformatic analysis suggested that MupW is a Rieske oxygenase-like enzyme in which the N-
terminal domains contain a [2Fe-2S] Rieske cluster involved in electron transfer reactions from a 
ferredoxin shuttle protein to a non-heme iron centre in the C-terminal domain. The conserved 
sequence motifs CXH and CXXH present two Cys and two His residues that ligate the iron atoms of the 
[2Fe-2S] cluster16. Within the C-terminal domain, a conserved DX2HX4H motif contains two His residues 
that ligate a non-heme iron centre and an aspartate residue16. All three universally conserved 
sequence motifs are found within the MupW protein with the exception that aspartate is substituted 
for glutamate but which has been shown to be functionally equivalent in other Rieske non-heme like 
oxygenases17 (Fig. 2a).   
Figure 2. Characterisation of the Rieske 
non-heme oxygenase MupW. a, 
Sequence alignment of the Rieske non-
heme oxygenases MupW and TmlW (the 
MupW equivalent in thiomarinol 
pathway) with the structurally 
characterised Rieske oxygenase 
naphthalene dioxygenase (NDO), 
conserved residues that ligate the [2Fe-
2S] cluster and Fe atom are highlighted 
in yellow. b, SDS-PAGE of His6-tagged 
recombinant MupW. c, UV absorption 
spectrum of purified MupW (4 mg/mL) in 
oxidised form (red line) and sodium 
dithionite-reduced form (blue line).  
 
 
The N-terminal His6-tagged recombinant MupW was heterologously overexpressed and purified to 
homogeneity (Fig. 2b) from Escherichia coli BL21 (DE3) to yield a brown-red enzyme solution that was 
characterised by ultraviolet-visible (UV) spectroscopy using standard techniques. The aerobically 
purified enzyme solution displayed characteristic [2Fe-2S] cluster absorbance peaks at around 330, 
 5 
 
460, and 560 nm, while upon reduction with sodium dithionite anaerobically, new absorption maxima 
were observed at around 520 nm18 (Fig. 2c). 
Rieske non-heme iron oxygenases are typically multicomponent enzymes that utilise a reductase and 
a ferredoxin partner for electron transfer from NAD(P)H to the terminal oxygenase that performs 
catalysis19. Sequence alignment and the UV spectrum (Supplementary Figure 1) suggests that MupT is 
the [2Fe-2S] Rieske cluster containing ferredoxin component, however, no cognate reductase partner 
has been identified within the mupirocin gene cluster7,8. Due to this limitation, O2 saturated putative 
substrates mupirocin W4 (7) and W5 (8) were then incubated with sodium dithionite-reduced MupW 
anaerobically, however, no turnover was observed by liquid chromatography–mass spectrometry (LC-
MS) analysis potentially due to extremely low yield of products (data not shown).  
 
Whole-cell biotransformations reveal MupW catalysed oxidations 
We next turned to in vivo biotransformations.  Substrates were incubated with whole live cells of the 
MupW overexpressing E. coli strain to obviate the redox partners and cofactor dependency. Such an 
approach has been widely used20-23 and was elegantly exemplified by Hauer and co-workers in their 
work on engineering Rieske non-heme iron oxygenases for the asymmetric dihydroxylation of 
alkenes21. Following Hauer’s protocol, we examined reactions of mupirocin W4 (7) and W5 (8) in 
whole-cell biotransformations using resting MupW overexpressing E. coli cells supplemented with 
glucose for in situ NAD(P)H regeneration. After incubation, mupirocin W4 (7, m/z 485 [M-H]-, Fig. 3a 
including appropriate controls) was fully converted to a product, identical in mass (m/z 499 [M-H]-) 
and HPLC retention time (11.9 mins) with those expected for desepoxy PA-B (4), apparently consistent 
with THP formation. When incubated with cells containing only the empty pET28a vector or denatured 
cells, the substrate mupirocin W4 (7) remains intact and no new product was detected (Fig. 3a iv), 
confirming that the MupW protein is indeed responsible for formation of the product. 
1D and 2D NMR spectra of the new product were, however, found to be significantly different from 
those of desepoxy PA-B (4) (Fig. 3b, Supplementary Figure 2). The structure of the new compound (9) 
was established by HRESI-MS and detailed analysis of 2D NMR data, including 1H-1H COSY, HSQC, 
HMBC and NOESY as shown in Fig. 3b and was determined to have a five membered-tetrahydrofuran 
(THF) ring formed between 5-OH and C8, and a hydroxymethyl group (C16) attached to C8 
(Supplementary Figure 3, Supplementary Table 1). Mupirocin W5 (8), with a shorter fatty acid chain 
than 7, was also fully converted to compound 10 assembled on a tetrasubstituted THF (Supplementary 
Figure 4). The structure of 10 was further supported by chemical derivatisation to afford acetonide 
11, which was further acetylated to yield 12, confirming the presence of the 8-hydroxymethyl group 
(Fig. 3c, Supplementary Methods).  
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To gain further insight into formation of the unexpected tetrahydrofurans a model study was 
undertaken. Treatment of alkene 13 with meta-chloroperbenzoic acid (mCPBA) was predicted to give 
a mixture of epoxides but these were not detected as spontaneous cyclisation occurred giving a 7:3 
mixture of diastereomeric tetrahydrofurans 14 and 15 in 80% yield (Fig. 3d, Supplementary Methods).  
Hence, formation 
 
Figure 3. Whole-cell biotransformations reveal MupW catalysed oxidations. a, LC-MS (total ion current, 
negative mode) traces of (i) mupirocin W4 (7), (ii) mupirocin W4 (7) incubated with MupW producing whole cells 
at 30 °C for 6 hours, (iii) mupirocin W4 (7) incubated with denatured MupW cells (boiled at 95 °C for 10 min), 
(iv) mupirocin W4 (7) incubated with cells harbouring the empty pET28a vector, (v) desepoxy PA-B (4) standard. 
b, 1H NMR spectra of (i) mupirocin W4 (7), (ii) new product 9, (iii) desepoxy PA-B (4) standard. c, Chemical 
derivatisation of compound 10. d, Model reaction showing spontaneous cyclisation to 5-membered ring 
products.  
 
of tetrahydrofurans 9 and 10 from incubation of 7 and 8 with MupW producing whole cells, is 
consistent with spontaneous cyclisation of an 8,16-epoxide. Epoxide ring opening to give Baldwin or 
anti-Baldwin behaviour has been the subject of detailed investigations24-26. In general, ring opening of 
-epoxides by a -hydroxyl is predicted to give a THF ring rather than a 6-membered THP.  Indeed, 
as discussed above, we have previously found in studies on mupirocin biosynthesis spontaneous 
cyclisation of epoxide 5 occurs to give tetrahydrofuran 615 (Fig. 1b).  
To investigate if tetrahydrofuran 9 is an intermediate in mupirocin biosynthesis, it was fed to cultures 
of the mmpE∆OR/∆mupW mutant of P. fluorescens but returned unchanged starting material. In 
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contrast, tetrahydropyran desepoxy PA-B (4) was readily transformed to PA-C (3) in the same mutant 
(Supplementary Figure 5). Thus, it is highly likely that the THF ring products 9 and 10 are artefacts 
spontaneously formed from the corresponding epoxides and are not intermediates in mupirocin 
biosynthesis. Hence THP ring formation must be an enzyme-controlled process.  
 
MupZ catalyses formation of the THP ring 
We thus turned our attention to identifying the enzyme responsible for the regioselective attack of 
the 5-hydroxy to C-16 to generate the 6-membered THP ring. We have previously identified the 
functions of most of the genes in the mupirocin gene cluster7,8 but several open reading frames with 
putative or unassigned functions remain. Prominent among the latter group was MupZ (Fig. 4a). 
Bioinformatic analysis indicated MupZ as a mixed α/β protein27, but its role in mupirocin biosynthesis 
had not been investigated.  
To investigate whether MupZ is indeed the missing epoxide hydrolase, whole-cell biotransformations 
were performed by incubating E. coli co-transformed with mupZ and mupW (Fig. 4b) with linear 
precursors. Incubation with mupirocin W4 (7) again yielded a product with the same retention time 
(11.9 mins) and mass (m/z 499 [M-H]-) as desepoxy PA-B (4) (Fig. 4c) and in this instance NMR 
spectroscopy confirmed this was indeed desepoxy PA-B (4) (Supplementary Figure 6). Similarly, 
mupirocin W5 (8) was fully converted to compound 16 containing a THP ring as opposed to the 
formation of product 10 with a THF ring catalysed by MupW alone (Supplementary Figure 6). Control 
reactions with denatured cells or with cells only expressing MupZ resulted in no product formation. 
To further confirm the function of MupZ, gene disruption of this enzyme within the mmpEΔOR mutant 
of P. fluorescens NCIMB 10586 was carried out using the two-step allelic exchange method 
(Supplementary Figure 7)28. The mmpEΔOR mutant of P. fluorescens produces mainly PA-C (3) with a 
10,11-double bond, rather than the less stable PA-A (1) with the 10,11-epoxide, albeit in low yield. 
Deletion of mupZ from the mmpEΔOR mutant abolished PA-C production and resulted in production 
of the two THF ring compounds 9 and 10, which were named mupirocin Z1 and Z2, respectively, and 
trace amounts of the acyclic metabolites mupirocin W4 (7) and W5 (8) (Fig. 4d). In trans expression of 
the mupZ gene in this mutant restored PA-C production (Fig. 4d).  
These results demonstrate that MupW catalyses the oxidation of the C8-C16 bond of acyclic 
mupirocins W4 (7) and W5 (8) to substrates for MupZ which subsequently catalyses regioselective 
cyclisation to generate the THP ring in mupirocin biosynthesis. Model studies are in accord with the 
oxidised intermediates being epoxides (Fig 3d) and our next goal was to gain further evidence by 
determining the structure of MupZ using X-ray crystallography and then to use molecular modelling 
and docking studies with the proposed substrate.  
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Figure 4. MupZ catalyses formation of the THP ring. a, Organisation of mupirocin gene cluster, see ref 5 for full 
annotation.  b, SDS-PAGE analysis of co-expression of MupW and MupZ, lanes 1-8: fractions from nickel column 
purification. c, LC-MS (total ion current, negative mode) traces of (i) mupirocin W4 (7), (ii) product formed by 
incubating mupirocin W4 (7) with E. coli cells overexpressing both MupW and MupZ, and (iii) desepoxy PA-B (4). 
d, HPLC traces of (i) mmpEΔOR mutant of P. fluorescens NCIMB 10586, (ii) mmpEΔOR/ΔmupZ double mutant, 
and (iii) mmpEΔOR/ΔmupZ complemented with mupZ in trans. e, Structures of products isolated from 
biotransformations with MupW and MupW/MupZ. 
 
The structure of MupZ was determined to 1.45 Å resolution by molecular replacement using the 
conserved protein MM_1583 from Methanosarcina mazei Go1 (PDB ID: 4DPO, 16% identity) as a 
search model and refined to an Rwork/Rfree of 16.1/19.5 (PDB ID: 6FXD, Supplementary Table 2). The 
asymmetric unit comprises two molecules of MupZ arranged as a symmetric homodimer (Fig. 5a). The 
enzyme adopts an α+β barrel-fold, formed from a central 5 stranded anti-parallel β-sheet augmented 
by three α-helices. DALI analysis29 of the MupZ structure reveals the absence of any closely structurally 
related (Z score >2.0) epoxide hydrolases in the Protein Data Bank (PDB). The only related enzymes 
identified were Lsd19 (PDB ID: 3RGA, Cα RMSD = 4.9), from the lasalocid A biosynthetic pathway30, and 
MonBI (PDB ID: 3WMD, Cα RMSD = 9.0), from the monensin pathway31. Both proteins are α+β barrel 
enzymes involved in epoxide ring opening cascades during the biosynthesis of polyether natural 
products. Neither exhibits significant structural identity to MupZ beyond retention of a core barrel 
fold. 
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Figure 5. The X-ray structure of MupZ (PDB ID: 6FXD) and proposed mechanism of cyclisation in mupirocin 
biosynthesis. a, Overall fold of MupZ dimer. b, Docked structure of putative epoxide substrate in the active site 
of MupZ. c, Structure of Lsd19 (PDB ID: 3RGA) with the isolasalocid-like THF-THF ligand in the active site30. d, 
Proposed mechanism of epoxide-opening cyclisation/THP formation in mupirocin biosynthesis.  
 
The epoxide hydrolase Lsd19B has been reported to utilise an Asp–Tyr dyad as a general acid–base 
pair to catalyse epoxide-opening to form cyclic ethers30. Docking and molecular modelling studies of 
MupZ with the proposed epoxide substrate identified an analogous acid–base pair of Glu54-Tyr41 in 
the enzyme active site (Fig. 5b and 5c). To investigate the role of these two residues the point mutants 
MupZ-Y41F and MupZ-E54Q were produced. Co-expression of MupW together with either MupZ-Y41F 
or MupZ-E54Q was successfully achieved using the same protocol as for the wild type MupZ 
(Supplementary Figure 8). Whole-cell biotransformation of substrates mupirocin W4 (7) or W5 (8) by 
MupZ-Y41F or MupZ-E54Q led to the formation of the 5-membered THF ring products in contrast to 
the THP ring products produced by WT-MupZ (Supplementary Figure 8). Together these data 
demonstrate the importance of these residues for catalysis. On the basis of these findings, we propose 
an acid–base mechanism of epoxide ring opening by MupZ where Glu54 acts to deprotonate the C5 
hydroxyl group of the substrate followed by protonation of the epoxide oxygen by Tyr41 and 
subsequent stabilisation of the developing transition leading to the 8-hydroxy THP ring structure (Fig. 
5d).  
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Discussion 
We have identified a tandem Rieske non-heme oxygenase/epoxide hydrolase (MupW/MupZ) that 
catalyses THP formation in the biosynthesis of the clinically important antibiotic mupirocin. These 
intriguing transformations couple the MupW catalysed selective oxidation of the non-activated C8-
C16 bond in complex acyclic precursors, mupirocins W4 (7) and W5 (8) to deliver substrates for MupZ 
which, in turn, catalyses regioselective cyclisation between the 5-OH and C-16 to generate the THP 
ring of desepoxy PA-B (4) and the analogue with a shorter fatty acid side-chain (16). In the absence of 
MupZ, the acyclic substrates 7 and 8 were transformed to tetrahydrofurans 9 and 10, with cyclisation 
occurring between 5-OH and C-8. Model chemical reactions as well as molecular modelling/docking 
studies are in accord with the acyclic biosynthetic precursors 7 and 8 being transformed to 8,16-
epoxides prior to ring formation via an anti-Baldwin 6-endo-tet ring closure catalysed by MupZ to 
generate the 8-hydroxy tetrahydropyran ring. 
There are two features of this enzyme-catalysed sequence which are particularly intriguing. First, 
chemically challenging functionalisation of non-activated bonds in the presence of numerous proximal 
functional groups is occurring with exquisite selectivity catalysed by the Rieske non-heme oxygenase, 
MupW. These enzymes are more usually associated with dihydroxylation of arenes and alkenes21, 
oxidative transformations of aliphatic compounds including monohydroxylations32 and desaturation33 
(probably via dehydration of a mono-hydroxylated species) of non-activated C-H groups and oxidative 
ring closures via a putative radical activation of an aliphatic C-H centre17. Further studies will be 
required to definitively prove that an epoxide is generated by MupW, which is a very unusual overall 
transformation for a Rieske non-heme oxygenase catalysed process. In contrast, α-ketoglutarate-
dependent (α-KG) oxygenases are known to give epoxides e.g. H6H is an α-KG oxygenase that 
hydroxylates (−)-atropine and then closes the newly introduced oxygen onto a neighbouring 
methylene to generate the epoxide of scopolamine34.  
The second unusual feature of tetrahydropyran formation in mupirocin biosynthesis is the anti-
Baldwin 6-endo-tet cyclisation catalysed by the epoxide hydrolase MupZ giving the hydroxy 
tetrahydropyran, desepoxy PA-B (4). There are very few examples where the nominally disfavoured 
THP has been shown to be the preferred product of an epoxide hydrolase enzyme. The flavin-
dependent monooxygenase (FMO) and an epoxide hydrolase pair AurC/AurD iteratively transform a 
terminal triene into the dioxabicyclo-octane system in the aurovertin fungal metabolite (Fig. 6a)35. 
Furthermore, the biosynthesis of the polyether lasalocid involves the FMO/epoxide hydrolase pair 
Lsd18/Lsd19 in which a 6-endo-tet cyclisation of epoxy-alcohol 17 generates the hydroxylated 
tetrahydropyran30,36 (Fig. 6a). High-resolution X-ray crystal structure of Lsd19 (also known as LasB) 
together with quantum-mechanical calculations studies have suggested a mechanism of general acid–
base catalysis and shown that 5-exo-tet cyclisation is energetically favoured under both acid- and base 
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catalysis30.  Indeed, competing 5-exo-tet cyclisations have proved problematic in the preparation of 
substrates for Lsd19 in lasalocid biosynthesis37 as well as in our work on the synthesis of epoxides as 
putative substrates for MupZ. 
 
Figure 6. Enzyme-catalysed reactions giving hydroxylated tetrahydropyrans via 6-endo-tet cyclisations. a, 
Examples of FMO/epoxide hydrolase cascades in (i) aurovertin35 and (ii) lasalocid30,36 biosynthesis. b, Formation 
of oxygen heterocycles in mupirocin biosynthesis.  
 
Based on the X-ray crystal structure of MupZ, molecular modelling and mutagenesis experiments, we 
propose that the acid-base pair Glu54 and Tyr41 are required in the active site to catalyse formation 
of the 8-hydroxytetrahydropyran ring in mupirocin biosynthesis (Fig. 5d). Tetrahydrofuran formation 
in our model studies combined with the functional characterisation of the catalytic dyad in MupZ 
provide support for an epoxide intermediate (Fig. 6b) generated by MupW from a non-activated 
alkane, an unusual overall transformation not previously reported for Rieske oxygenases38.  
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Methods 
General experimental procedures. Column chromatographic separations were carried out by using 
MCI gel CHP20P (75-150 μm, Mitsubishi Chemical Corporation, Tokyo, Japan) or Sephadex LH-20 
(Pharmacia Biotech AB, Uppsala, Sweden) as packing materials. LC-MS data were obtained on a 
Waters LCMS system comprising Waters 2767 autosampler, Waters 515 HPLC pump, Waters 2998 
Diode Array detector, Waters 2424 ELS detector and Waters Quatro Micro mass spectrometer. HPLC 
grade H2O and MeCN were added with 0.05% formic acid as solvent system. Analytical LC-MS data 
were obtained using a Phenomenex Kinetex column (C18, 250 x 4.60 mm, 5 µm) at a flow rate of 1 
mL/min. Preparative HPLC purification were carried out using a Phenomenex Kinetex column (C18, 250 
x 21.20 mm, 5 µm) at a flow rate of 16 mL/min. HRESIMS data were obtained on a Bruker Daltonics 
micrOTOF II instrument. 1H and 2D NMR data were collected on Bruker Cryo500 or Bruker Cryo700 
Micro-Coil NMR spectrometers, 13C NMR data were collected on Bruker Cryo500 NMR spectrometer. 
For NMR spectra of the compounds in this article, see Supplementary Figures 9-48. 
Isolation and purification of mupirocin W4 (7) and W5 (8) from mmpEΔOR/ΔmupW double mutant 
of P. fluorescens NCIMB 10586. A 1.0 L scale fermentation of mmpEΔOR/ΔmupW P. fluorescens 
NCIMB 10586 was carried out as per general procedure that has been described previously10. The 
crude extract was subjected to MCI gel CHP20P and then Sephadex LH-20 column chromatography 
and eluted with MeOH to give 5 fractions. Fraction 5 was further purified by HPLC eluted with a 
gradient of 20 to 70% of MeCN in water over 20 minutes to yield mupirocin W4 (7, 1.0 mg) and 
mupirocin W5 (8, 1.5 mg). Mupirocin W4 (7): ESI-MS: m/z = 485 [M-H]-; 1H NMR (500 MHz, CD3OD) 
and 13C NMR (125 MHz, CD3OD) data are shown in Supplementary Table 1. Mupirocin W5 (8): ESI-MS: 
m/z = 457 [M-H]-; 1H NMR (500 MHz, CD3OD): δH 5.79 (1H, br s, H-2), 5.47 (1H, m, H-10), 5.40 (1H, dd, 
J = 15.4, 7.7 Hz, H-11), 4.08 (2H, t, J = 6.6 Hz, H-7’), 3.98 (1H, m, H-5), 3.62 (1H, dq, J = 6.3, 4.9 Hz, H-
13), 3.56 (1H, dd, J = 8.6, 4.9 Hz, H-6), 3.44 (1H, dd, J = 8.6, 2.9 Hz, H-7), 2.54 (1H, d, J = 14.3 Hz, H-4), 
2.31 (1H, m, H-9), 2.29 (1H, m, H-4), 2.26 (2H, m, H-2’), 2.21 (3H, s, H-15), 2.15 (1H, m, H-12), 1.93 (1H, 
m, H-8), 1.88 (1H, m, H-9), 1.66 (2H, m, H-6’), 1.62 (2H, m, H-3’), 1.35-1.45 (4H, m, H-4’ and H-5’), 1.10 
(3H, d, J = 6.4 Hz, H-14), 0.99 (3H, d, J = 6.9 Hz, H-17), 0.98 (3H, d, J = 6.7 Hz, H-16); 13C NMR (125 MHz, 
CD3OD): δC 179.0 (C, C-1’), 168.4 (C, C-1), 159.6 (C, C-3), 134.5 (CH, C-11), 131.3 (CH, C-10), 118.5 (CH, 
C-2), 78.3 (CH, C-7), 75.1 (CH, C-6), 72.5 (CH, C-5), 72.3 (CH, C-13), 64.7 (CH2, C-7’), 45.3 (CH, C-12), 
44.1 (CH2, C-4), 36.2 (CH, C-8), 35.4 (CH2, C-2’), 34.3 (CH2, C-9), 29.9 (CH2, C-5’), 29.7 (CH2, C-6’), 26.9 
(CH2, C-4’), 26.2 (CH2, C-3’), 20.2 (CH3, C-14), 19.2 (CH3, C-15), 17.2 (CH3, C-16), 16.6 (CH3, C-17). 
Expression and purification of proteins. The mupW and mupZ genes were amplified from P. 
fluorescens NCIMB 10586 genomic DNA by polymerase chain reaction (PCR), with the following 
primers (lower case letters indicate appropriate sequences homologous to target vectors): mupW-For: 
5’-tgggtcgcggatccgaattcATGAAAAGCAAATTGATCGAGC-3’; mupW-Rev: 5’-caagcttgtcgacggagctcT-
CAATCGCGCCTGTCAAGATA-3’; mupZ-For: 5’-aagttctgtttcaggcccgATGAATCGCACCTGCATGGCCATGCC-
3’; mupZ-Rev: 5’-atggtctagaaagctttaCGCCACCACAGACGGCCGGCTG-3’. The mupW and mupZ PCR 
products were then introduced into pET28a vector (pre-linearized with EcoRI and SacI), and pOPINF 
(pre-linearized with KpnI and HindIII), respectively, using the In-Fusion HD Cloning Kit (Clonetech). The 
resultant plasmids were verified by sequencing and transformed into E. coli BL21 (DE3). For MupW, 
the resultant strain was inoculated into 20 ml LB medium supplemented with 100 μg/ml kanamycin 
and incubated overnight at 37 °C/200 rpm. The overnight culture was added into 1 L of auto induction 
medium LB broth base including trace elements (FORMEDIUMTM) containing 100 μg/ml kanamycin 
and incubated at 37 °C/200 rpm until the optical density of the cultures at 600 nm had reached 0.6, 
and following incubation was changed to 18 °C/200 rpm for overnight. For MupZ, LB broth medium 
supplemented with 100 μg/ml carbenicillin was used instead of auto induction medium, protein 
expression was induced by the addition of IPTG to a final concentration of 0.5 mM until the optical 
density of the cultures at 600 nm had reached 0.6, followed by incubation at 18 °C/200 rpm for 
overnight. Co-expression of MupW and MupZ followed the same procedure as MupW but with auto 
induction medium supplemented with both kanamycin and carbenicillin. Synthetic DNAs were 
purchased from Thermo Fisher Scientific for MupZ-Y41F and MupZ-E54Q point mutants, cloning and 
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expression followed the same protocol as for the wild type. Cells were then harvested by 
centrifugation (4 °C, 4500 rpm for 30 min) and resuspended in Buffer A (50 mM Tris/HCl pH 7.5, 150 
mM NaCl). The cells were lysed by sonication (6 × 10 s pulsed cycle) on ice, and the debris was removed 
by centrifugation (4 °C, 15000 rpm for 30 min). The clarified supernatant was loaded onto a pre-
equilibrated Ni-NTA agarose column, which was then washed with a gradient of Buffer B (50 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 1 M imidazole). Fractions containing the target protein of interest, as 
established by monitoring the absorbance of the column eluent at 280 nm followed by SDS-PAGE 
analysis, were pooled and concentrated. Concentrated protein samples were subjected to Superdex 
75 or 200 size exclusion column for further purification, eluted with Buffer A to yield final protein 
samples with >95% purity. 
Whole-cell biotransformation. In in vivo biotransformations, 50 mL of overnight culture of E. coli BL21 
(DE3) cells overexpressing MupW or both MupW and MupZ in auto induction medium were 
centrifuged at 6000 rpm for 5 min, cell pellets were resuspended in 2 mL of 100 mM potassium 
phosphate buffer pH 7.2 supplemented with 20 mM glucose, 0.4 mg of substrates mupirocin W4 (7) 
or W5 (8) dissolved in 40 μl of MeOH were then added and the reactions were incubated at 30 °C, 180 
rpm for 6 h. As negative controls, denatured corresponding cells or cells harbouring empty vectors 
were used. Reactions were quenched by adding equal volume of acetonitrile, vortexed and 
centrifuged. The acetonitrile layer was injected for LC-MS analysis. Full conversions from substrates 
to products were observed according to HPLC analysis. Products were cleaned by preparative HPLC 
prior to NMR analysis. Compound 9 (0.2 mg): HR-ESI-MS: m/z = 523.2861 [M+Na]+ (523.2878 calcd for 
C26H44O9Na); 1H NMR (700 MHz, CD3OD) and 13C NMR (125 MHz, CD3OD) data are shown in 
Supplementary Table 1. Compound 10 (0.2 mg): HR-ESI-MS: m/z = 471.2602 [M-H]- (471.2600 calcd 
for C24H39O9); 1H NMR (700 MHz, CD3OD): δH 5.78 (1H, br s, H-2), 5.48 (1H, m, H-11), 5.47 (1H, m, H-
10), 4.08 (2H, t, J = 6.6 Hz, H-7’), 4.02 (1H, m, H-5), 4.00 (1H, d, J = 5.6 Hz, H-7), 3.76 (1H, t, J = 6.2 Hz, 
H-6), 3.68 (1H, d, J = 11.6 Hz, H-16), 3.62 (1H, dq, J = 6.3, 4.9 Hz, H-13), 3.58 (1H, d, J = 11.6 Hz, H-16), 
2.48 (1H, dd, J = 13.8, 4.0 Hz, H-4), 2.32 (1H, dd, J = 14.1, 8.4 Hz, H-4), 2.24 (2H, m, H-9), 2.22 (2H, m, 
H-2’), 2.21 (3H, s, H-15), 2.16 (1H, m, H-12), 1.66 (2H, m, H-6’), 1.62 (2H, m, H-3’), 1.35-1.45 (4H, m, H-
4’ and H-5’), 1.11 (3H, d, J = 6.3 Hz, H-14), 1.01 (3H, d, J = 6.9 Hz, H-17); 13C NMR (125 MHz, CD3OD): 
δC 181.1 (C, C-1’), 168.3 (C, C-1), 158.3 (C, C-3), 137.5 (CH, C-11), 126.6 (CH, C-10), 118.6 (CH, C-2), 86.9 
(C, C-8), 81.5 (CH, C-5), 76.3 (CH, C-6), 75.8 (CH, C-7), 72.1 (CH, C-13), 65.1 (CH2, C-16), 64.9 (CH2, C-
7’), 46.1 (CH2, C-4), 45.4 (CH, C-12), 40.6 (CH2, C-9), 37.3 (CH2, C-2’), 30.3 (CH2, C-4’ or C-5’), 29.8 (CH2, 
C-6’), 27.0 (CH2, C-5’ or C-4’), 27.0 (CH2, C-3’), 20.4 (CH3, C-14), 19.5 (CH3, C-15), 16.6 (CH3, C-17). 
Compound 16 (0.2 mg): HR-ESI-MS: m/z = 471.2591 [M-H]- (471.2600 calcd for C24H39O9); 1H NMR (700 
MHz, CD3OD): δH 5.75 (1H, br s, H-2), 5.57 (1H, m, H-10), 5.48 (1H, dd, J = 15.5, 7.8 Hz, H-11), 4.08 (2H, 
t, J = 6.6 Hz, H-7’), 3.72 (1H, d, J = 2.9 Hz, H-7), 3.64 (1H, m, H-5), 3.62 (1H, m, H-13), 3.44 (1H, d, J = 
10.9 Hz, H-16), 3.35 (1H, m, H-6), 3.32 (1H, m, H-16), 2.66 (1H, d, J = 14.4 Hz, H-4), 2.33 (2H, m, H-9), 
2.26 (2H, t, J = 6.6 Hz, H-2’), 2.20 (1H, m, H-4), 2.18 (1H, m, H-12), 2.18 (3H, s, H-15), 1.66 (2H, m, H-
6’), 1.62 (2H, m, H-3’), 1.35-1.45 (4H, m, H-4’ and H-5’), 1.11 (3H, d, J = 6.4 Hz, H-14), 1.01 (3H, d, J = 
6.9 Hz, H-17); 13C NMR (observed via HSQC and HMBC): δC 168.4 (C, C-1), 159.0 (C, C-3), 137.4 (CH, C-
11), 126.9 (CH, C-10), 118.3 (CH, C-2), 75.3 (CH, C-5), 74.1 (CH, C-7), 72.8 (C, C-8), 72.1 (CH, C-13), 70.9 
(CH, C-6), 69.7 (CH2, C-16), 64.7 (CH2, C-7’), 45.7 (CH, C-12), 44.0 (CH2, C-4), 39.8 (CH2, C-9), 36.1 (CH2, 
C-2’), 30.3 (CH2, C-4’ or C-5’), 29.8 (CH2, C-6’), 27.0 (CH2, C-5’ or C-4’), 26.5 (CH2, C-3’), 20.2 (CH3, C-14), 
19.4 (CH3, C-15), 16.5 (CH3, C-17). 
Gene Inactivation and Complementation of mupZ. Targeted gene inactivation was achieved by the 
two-step allelic exchange method28, as illustrated in Supplementary Figure 7. Two fragments sized 327 
bp and 623 bp respectively upstream and downstream of mupZ were amplified from P. fluorescens 
NCIMB 10586 genomic DNA by PCR with the following primers (lower case letters indicate appropriate 
sequences homologous to target vector): mupZ-Up-For: 5’-acgaattcgagctcg-
ATCCTAGCGTCCTCATCGTCT-3’; mupZ-Up-Rev: 5’-GTAGATACATCGGGTCCATTGAAGCTGAAACCGTAG-
3’; mupZ-Down-For: 5’-TTTCAGCTTCAATGGACCCGATGTATCTACAAGAGGC-3’; mupZ-Down-Rev: 5’-
ggccagtgccaagctCTACCAGGATCCAGACATTCAG-3’. The two PCR fragments were spliced together by 
overlap extension PCR using the upstream forward primer and the downstream reverse primer. The 
resultant 950 bp mutant allele was cloned into KpnI/HindIII-digested pEX18Tc by In-Fusion HD Cloning 
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Kit, yielding the allelic exchange suicide vector pEX18Tc-mupZKO, which was then transformed into E. 
coli S17.1 (λ pir+). 1.5 ml of the overnight E. coli donor strain containing plasmid pEX18Tc-mupZKO and 
0.5 ml of the mmpEΔOR mutant of P. fluorescens NCIMB 10586 recipient strain were centrifuged at 
10,000g for 5 min at room temperature. Each cell pellet was collected and resuspended in 50 μl of LB 
and then combined. This cell mixture was transferred onto the middle of a prewarmed LB agar plate. 
The ‘puddle’ was allowed to dry on the agar surface and incubated overnight at 30 °C. The mating 
puddle was then scraped off and resuspended in 1.0 ml of sterile saline solution. 10-, 100-, and 500-
µl aliquots were spread on LB agar plates supplemented with tetracycline (15 µg/ml) and carbenicillin 
(50 µg/ml) and incubated for 72 hours at 30 °C. Single colonies were picked from above LB plates and 
streaked onto no-salt LB + 15% (wt/vol) sucrose agar, followed by incubation for 48 hours at 30 °C. 
Colonies were screened for the targeted knockout mutant by PCR using the upstream forward and the 
downstream reverse primer pair (Supplementary Figure 7). For complementation, the mupZ gene was 
cloned into pEX18Tc using primers as follows: mupZ-Comp-For: 5’-
acgaattcgagctcgATGAATCGCACCTGCATGGC-3’; mupZ-Comp-Rev: 5’-
ggccagtgccaagctTCACGCCACCACAGACGG-3’. Plasmid pEX18Tc-mupZ was introduced into the 
mmpEΔOR/ΔmupZ mutant of P. fluorescens NCIMB 10586 by the same conjugation method as 
described above. Fermentation, isolation and purification of metabolites followed the same general 
procedure described previously10. All structures were confirmed by NMR spectroscopy. 
 
Crystallisation, data collection and structure determination of MupZ. Crystals of MupZ were initially 
obtained using the sitting drop vapor diffusion method at 20 °C from the Morpheus II screen 
(Molecular Dimension Limited). Diffraction quality crystals were grown by microseeding using the 
hanging drop vapour diffusion method, mixing 1.0 μL of protein solution (5 mg/ml) with 1.0 μL of 
reservoir solution comprising 100 mM amino acids II, 0.1 M MOPSO, Bis-Tris pH 6.5 and 25% w/v PEG 
4000, 40% w/v 1,2,6-hexanetriol. X-ray diffraction data were collected from a single crystal to a 1.45 Å 
resolution at beamline I03 of Diamond Light Source, UK. Data were indexed and integrated with 
DIALS39 using xia240. MupZ crystals belong to space group C121 with unit cell parameters a=42.33Å, 
b=80.09Å and c=78.82Å. The asymmetric unit contains 1 MupZ dimer of identical 14 kDa subunits 
with a solvent content of 39%. Initial phases were determined by molecular replacement with the 
program MOLREP41 in CCP4i242,43. A single subunit of the conserved protein MM_1583 from 
Methanosarcina mazei Go1 (PDB ID: 4DPO) was used as a search model. Prior to MR the model was 
truncated to remove any unstructured loops. Once a solution was found, about 80% of the model was 
automatically built using BUCCANEER44 (CCP4i2). The resulting electron density allowed iterative 
rounds of model building and restrained refinement with in Coot45 and REFMAC546 (CCP4i2). Data 
collection, phasing and refinement statistics are provided in Supplementary Table 2. In the final model 
of MupZ all the native sequence of the protein (2-122 residues) is clearly visible, with short section 
(VLFQGP) of the vector derived tag also present in subunit A. The refined coordinates have been 
deposited in the PDB with accession code 6FXD. 
Molecular docking. Molecular docking of the expected epoxide substrate of MupZ was performed 
using the obtained crystal structure (without crystallographically determined water molecules). The 
substrate structure, truncated by -(CH2)3-CO2H for docking feasibility, was initially built with 
GaussView and optimized at the B97D/6-31+G(d,p) level in Gaussian0947; the C5-C6, C6-C7 and C7-C8 
bonds were subsequently rotated to obtain a catalytically relevant conformation. AutoDockTools 1.5.4 
was used to merge the non-polar hydrogens and define rotable bonds. During docking, all formally 
single rotable bonds were allowed to change, apart from the aforementioned C5-C6, C6-C7 and C7-C8 
bonds. The side-chains of Glu54 and Asn73 were also allowed to rotate. Subsequently, docking was 
performed with AutoDock Vina 1.1.248, using a grid of 14×22×18 Å centered on the active site cavity. 
The exhaustiveness was set to 25. Docking poses where the truncated part was placed such that the -
(CH2)3-CO2H could not feasibly fit in to the enzyme active site cleft were discarded. The top pose 
indicated a catalytically feasible orientation, and the -(CH2)3-CO2H was build back onto the substrate 
manually, in line with the protein structure (Fig. 5b). Based on the docked pose of the (truncated) 
substrate obtained, the system was set up for molecular mechanics simulation using the PREP protocol 
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of Enlighten (https://github.com/marcvanderkamp/enlighten/). This uses the AmberTools49 program 
reduce to add hydrogens, and PropKa 3.150,51 to assign protonation states and His tautomers. All 
residues in their standard protonation states (in line with predicted pKa values by PropKa 3.1). All 
crystallographically determined water molecules were kept apart from water molecules in the active 
site cleft overlapping with the docked pose. Subsequently, the AmberTools program tleap was used 
to add additional waters to form a sphere of 20 Å around C5 of the substrate. Subsequently, the 
Enlighten STRUCT protocol was used for structural optimization (comprising of brief simulated 
annealing followed by energy minimization). The AMBER ff14SB force field for the protein52, together 
with the TIP3P water model and General Amber Force Field parameters (GAFF)53 for the substrate 
(assigned with Antechamber). The results from the structural optimization indicate a catalytically 
feasible substrate orientation, with Glu54 in line to abstract a proton from the hydroxyl group 
attached to C7, and Tyr41 interacting with the epoxide oxygen; Tyr41 could then donate a proton after 
(or concerted with) ring closure. 
 
Data availability 
The data that support the plots within this paper and other findings of this study are available from 
the corresponding author upon reasonable request. X-ray crystallographic data are available in the 
EMBL-EBI PDB under the accession number 6FXD. 
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